Trials / Completed
CompletedNCT02718443
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Vaximm GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VXM01 | Oral immunotherapy targeting VEGFR2 |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-08-01
- Completion
- 2018-07-01
- First posted
- 2016-03-24
- Last updated
- 2018-10-19
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02718443. Inclusion in this directory is not an endorsement.